Laura Chico
Stock Analyst at Wedbush
(2.36)
# 1,455
Out of 4,435 analysts
161
Total ratings
39.22%
Success rate
-0.41%
Average return
Main Sectors:
31 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Neutral | $47 → $48 | $40.14 | +19.58% | 9 | May 31, 2024 | |
| NBIX Neurocrine Biosciences | Reiterates: Outperform | $152 | $135.41 | +12.25% | 7 | May 29, 2024 | |
| ARDX Ardelyx | Reiterates: Outperform | $15 | $6.86 | +118.66% | 11 | May 24, 2024 | |
| AVTE Aerovate Therapeutics | Reiterates: Outperform | $41 | $17.45 | +134.96% | 2 | May 22, 2024 | |
| PEPG PepGen | Reiterates: Outperform | $20 | $16.33 | +22.47% | 7 | May 15, 2024 | |
| VYGR Voyager Therapeutics | Maintains: Neutral | $10 → $8 | $8.40 | -4.76% | 2 | May 14, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $33 → $38 | $21.61 | +75.84% | 4 | May 10, 2024 | |
| ATXS Astria Therapeutics | Reiterates: Outperform | $22 | $9.47 | +132.31% | 7 | May 10, 2024 | |
| XENE Xenon Pharmaceuticals | Maintains: Outperform | $51 → $50 | $38.07 | +31.34% | 7 | May 10, 2024 | |
| PHVS Pharvaris | Maintains: Outperform | $35 → $31 | $18.96 | +63.50% | 5 | May 9, 2024 | |
| VIGL Vigil Neuroscience | Reiterates: Outperform | $22 | $3.18 | +591.82% | 5 | May 8, 2024 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $31 → $30 | $18.56 | +61.64% | 6 | May 8, 2024 | |
| GOSS Gossamer Bio | Reiterates: Outperform | $4 | $0.59 | +577.97% | 2 | May 8, 2024 | |
| LBPH Longboard Pharmaceuticals | Maintains: Outperform | $32 → $34 | $18.87 | +80.18% | 5 | May 3, 2024 | |
| BIIB Biogen | Maintains: Neutral | $213 → $215 | $224.94 | -4.42% | 12 | Apr 25, 2024 | |
| TVTX Travere Therapeutics | Reiterates: Outperform | $13 | $7.42 | +75.20% | 7 | Apr 17, 2024 | |
| SAGE Sage Therapeutics | Reiterates: Neutral | $24 | $11.11 | +116.02% | 5 | Apr 17, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $67 → $57 | $39.25 | +45.22% | 11 | Apr 17, 2024 | |
| EWTX Edgewise Therapeutics | Reiterates: Outperform | $26 | $17.13 | +51.78% | 6 | Apr 16, 2024 | |
| RLYB Rallybio | Maintains: Outperform | $13 → $11 | $1.67 | +558.68% | 4 | Apr 11, 2024 | |
| OVID Ovid Therapeutics | Initiates: Outperform | $8 | $3.06 | +161.44% | 1 | Apr 5, 2024 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $13 → $17 | $14.62 | +16.28% | 5 | Mar 26, 2024 | |
| VERA Vera Therapeutics | Maintains: Neutral | $21 → $34 | $37.99 | -10.50% | 6 | Mar 21, 2024 | |
| DSGN Design Therapeutics | Reiterates: Neutral | $5 | $4.05 | +23.46% | 5 | Mar 20, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $39 → $40 | $11.95 | +234.73% | 6 | Feb 28, 2024 | |
| PRAX Praxis Precision Medicines | Maintains: Neutral | $16 → $29 | $47.46 | -38.90% | 5 | Jan 12, 2024 | |
| BMRN BioMarin Pharmaceutical | Initiates: Market Perform | n/a | $75.07 | - | 4 | Sep 28, 2023 | |
| TSHA Taysha Gene Therapies | Maintains: Outperform | $9 → $5 | $3.43 | +45.77% | 2 | Aug 12, 2022 | |
| BHVN Biohaven Pharmaceutical Holding Company | Downgrades: Neutral | $149 | $35.10 | +323.08% | 1 | Aug 8, 2022 | |
| CRBP Corbus Pharmaceuticals Holdings | Initiates: Outperform | n/a | $42.80 | - | 1 | Jan 19, 2018 | |
| CDTX Cidara Therapeutics | Initiates: Strong Buy | $280 | $12.69 | +2,106.46% | 1 | Apr 21, 2017 |
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Neutral
Price Target: $47 → $48
Current: $40.14
Upside: +19.58%
Neurocrine Biosciences
May 29, 2024
Reiterates: Outperform
Price Target: $152
Current: $135.41
Upside: +12.25%
Ardelyx
May 24, 2024
Reiterates: Outperform
Price Target: $15
Current: $6.86
Upside: +118.66%
Aerovate Therapeutics
May 22, 2024
Reiterates: Outperform
Price Target: $41
Current: $17.45
Upside: +134.96%
PepGen
May 15, 2024
Reiterates: Outperform
Price Target: $20
Current: $16.33
Upside: +22.47%
Voyager Therapeutics
May 14, 2024
Maintains: Neutral
Price Target: $10 → $8
Current: $8.40
Upside: -4.76%
Dianthus Therapeutics
May 10, 2024
Maintains: Outperform
Price Target: $33 → $38
Current: $21.61
Upside: +75.84%
Astria Therapeutics
May 10, 2024
Reiterates: Outperform
Price Target: $22
Current: $9.47
Upside: +132.31%
Xenon Pharmaceuticals
May 10, 2024
Maintains: Outperform
Price Target: $51 → $50
Current: $38.07
Upside: +31.34%
Pharvaris
May 9, 2024
Maintains: Outperform
Price Target: $35 → $31
Current: $18.96
Upside: +63.50%
Vigil Neuroscience
May 8, 2024
Reiterates: Outperform
Price Target: $22
Current: $3.18
Upside: +591.82%
Denali Therapeutics
May 8, 2024
Maintains: Outperform
Price Target: $31 → $30
Current: $18.56
Upside: +61.64%
Gossamer Bio
May 8, 2024
Reiterates: Outperform
Price Target: $4
Current: $0.59
Upside: +577.97%
Longboard Pharmaceuticals
May 3, 2024
Maintains: Outperform
Price Target: $32 → $34
Current: $18.87
Upside: +80.18%
Biogen
Apr 25, 2024
Maintains: Neutral
Price Target: $213 → $215
Current: $224.94
Upside: -4.42%
Travere Therapeutics
Apr 17, 2024
Reiterates: Outperform
Price Target: $13
Current: $7.42
Upside: +75.20%
Sage Therapeutics
Apr 17, 2024
Reiterates: Neutral
Price Target: $24
Current: $11.11
Upside: +116.02%
Apellis Pharmaceuticals
Apr 17, 2024
Maintains: Neutral
Price Target: $67 → $57
Current: $39.25
Upside: +45.22%
Edgewise Therapeutics
Apr 16, 2024
Reiterates: Outperform
Price Target: $26
Current: $17.13
Upside: +51.78%
Rallybio
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $1.67
Upside: +558.68%
Ovid Therapeutics
Apr 5, 2024
Initiates: Outperform
Price Target: $8
Current: $3.06
Upside: +161.44%
Stoke Therapeutics
Mar 26, 2024
Maintains: Outperform
Price Target: $13 → $17
Current: $14.62
Upside: +16.28%
Vera Therapeutics
Mar 21, 2024
Maintains: Neutral
Price Target: $21 → $34
Current: $37.99
Upside: -10.50%
Design Therapeutics
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $4.05
Upside: +23.46%
Viridian Therapeutics
Feb 28, 2024
Maintains: Outperform
Price Target: $39 → $40
Current: $11.95
Upside: +234.73%
Praxis Precision Medicines
Jan 12, 2024
Maintains: Neutral
Price Target: $16 → $29
Current: $47.46
Upside: -38.90%
BioMarin Pharmaceutical
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $75.07
Upside: -
Taysha Gene Therapies
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $3.43
Upside: +45.77%
Biohaven Pharmaceutical Holding Company
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $35.10
Upside: +323.08%
Corbus Pharmaceuticals Holdings
Jan 19, 2018
Initiates: Outperform
Price Target: n/a
Current: $42.80
Upside: -
Cidara Therapeutics
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $12.69
Upside: +2,106.46%